Real-World Experience in Toxicity with Bevacizumab in Indian Cancer Patients

Background Bevacizumab, a humanized monoclonal antibody, known to block the binding of all known vascular endothelial growth factor-A isomers to their receptors, is used in solid cancers, especially in advanced settings where its role is proven to be stronger than localized stages. Furthermore, vari...

Descripción completa

Detalles Bibliográficos
Autores principales: Patil, Pratik P., Rangaraju, Ranga R., Abbas, Waseem, Garg, Sunny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Thieme Medical and Scientific Publishers Private Ltd 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460349/
https://www.ncbi.nlm.nih.gov/pubmed/34568227
http://dx.doi.org/10.1055/s-0041-1729445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460349/
https://www.ncbi.nlm.nih.gov/pubmed/34568227
http://dx.doi.org/10.1055/s-0041-1729445

Ejemplares similares